{"id":46929,"date":"2024-04-30T09:22:09","date_gmt":"2024-04-30T08:22:09","guid":{"rendered":"https:\/\/www.innovationnewsnetwork.com\/?p=46929"},"modified":"2024-04-30T09:22:09","modified_gmt":"2024-04-30T08:22:09","slug":"microarray-vaccine-patch-effective-against-measles-and-rubella","status":"publish","type":"post","link":"https:\/\/www.innovationnewsnetwork.com\/microarray-vaccine-patch-effective-against-measles-and-rubella\/46929\/","title":{"rendered":"Microarray vaccine patch effective against measles and rubella"},"content":{"rendered":"
The patch \u2013 the size of a small sticking plaster and developed by Micron Biomedical Inc \u2013 offers pain-free vaccination<\/a> and has shown to be as effective as traditional measles and rubella injections.<\/p>\n Measles and rubella are highly contagious and are a major cause of death among children and young adults<\/a>.<\/p>\n It is hoped that the needle-free vaccine will help boost vaccination coverage in low-resource settings.<\/p>\n The vaccine patch trial was conducted by researchers from the Medical Research Council (MRC) Unit The Gambia at the London School of Hygiene & Tropical Medicine (LSHTM).<\/p>\n The study involved 45 adults (18-40 years old), 120 toddlers (15-18 months old) and 120 infants (9-10 months old).<\/p>\n Over 90% of infants were protected against measles, and all infants were protected from rubella using the vaccine patch, which uses microscopic needles to deliver the dose.<\/p>\n The trial found no safety concerns with administering the measles and rubella vaccine via microarray patches.<\/p>\n Professor Ed Clarke, a paediatrician who leads the Vaccines and Immunity Theme at MRC Unit The Gambia at LSHTM and co-author, said: \u201cAlthough it\u2019s early days, these are extremely promising results which have generated a lot of excitement.<\/p>\n \u201cThey demonstrate for the first time that vaccines can be safely and effectively given to babies and young children using microarray patch technology.<\/p>\n \u201cMeasles vaccines are the highest priority for delivery using this approach, but the delivery of other vaccines using microarray patches is also now realistic. Watch this space.\u201d<\/p>\n For adequate protection, the WHO recommends at least 95% two-dose measles vaccine coverage, and rubella requires 80% population immunity.<\/p>\n Microarray vaccines have been targeted as a major innovation to meet immunisation targets in low-resource settings.<\/p>\n Patches offer several advantages over conventional jabs, as they are easier to transport, significantly reduce the need for cold storage, and do not need to be administered by a medical professional.<\/p>\n This makes vaccine patches ideal for sub-Saharan Africa, and volunteers are expected to be able to administer the vaccines after brief training.<\/p>\n Moreover, as they do not use needles, the patches do not risk \u2018needlestick\u2019 injuries that can spread hepatitis and HIV infections.<\/p>\n Even in well-resourced countries with robust vaccination programmes, vaccine patches could offer a convenient and pain-free alternative to boost vaccination rates and overcome vaccine hesitancy<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":" A randomised trial has demonstrated the safety and efficacy of a microarray vaccine patch in protecting against measles and rubella.<\/p>\n","protected":false},"author":15,"featured_media":46930,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[10551],"tags":[849,24360],"acf":[],"yoast_head":"\nEffective protection against measles and rubella<\/h3>\n
Increasing vaccination coverage<\/h3>\n